FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia
The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!